Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

  • Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system
  • Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point
  • Ketamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at subanesthetic doses

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, recently completed a study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics (

Results of the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point.

“These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction,” said Eric Weisblum, CEO of Silo Pharma. “This data is extremely promising for patients suffering from fibromyalgia and rheumatoid arthritis. Additionally, I am delighted to report that day seven and day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”

Ketamine is typically used to induce and maintain anesthesia. The medication can produce a trance-like state that provides sedation, amnesia, and pain relief ( While some anesthetic agents often employed cause serious side effects (, ketamine anesthesia typically preserves airway reflexes and breathing while stimulating heart function and increasing blood pressure. 

Interest in ketamine has expanded beyond traditional uses to include treatment for depression ( and chronic pain ( at subanesthetic doses. The drug is on the World Health Organization’s List of Essential Medicines ( and has been referred to as a “major advance in the treatment of depression of the past 50 years” (

Silo Pharma aims to leverage the effects of ketamine via a patented administration method developed in partnership with Zylo Therapeutics Inc. called “Z-pod”. The company’s ketamine study aimed to demonstrate that Z-pod can hold and distribute ketamine and time-release the drug while diminishing potential hallucinogenic side effects. Besides ketamine, Z-pod is also being tested by Silo for other medicines, including psilocybin.

Silo Pharma Inc. is dedicated to researching and developing innovative pharmaceutical solutions that help people suffering from indications such as chronic pain, rheumatoid arthritis, fibromyalgia, post-traumatic stress disorder (“PTSD”), Parkinson’s disease, Alzheimer’s disease, and other rare neurological disorders. The company identifies and partners with leading medical universities, providing financial resources that catalyze the progress of cutting-edge research through the clinical stage and into commercialization. 

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050